Monoclonal antibody anti-PBP2a protects mice against MRSA (methicillin-resistant Staphylococcus aureus) infections
Open Access
- 27 November 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (11) , e0225752
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a multidrug-resistant bacterium responsible for serious nosocomial and community-acquired infections worldwide. Since few antibiotics are effective for treating MRSA infections, the development of new therapies is of great importance. Previous studies demonstrated that PBP2a is a target that generates protective antibodies against MRSA. A murine monoclonal antibody (MAb) that recognizes PBP2a from MRSA strains was previously isolated and characterized. In this report, we evaluated the biodistribution of this MAb in blood and tissues, as well as the extent of protection conferred using prophylactic and therapeutic assays compared to vancomycin treatment. Biodistribution was evaluated 12–96 h after MAb administration. It predominantly remained in the serum, but it was also detectable in the kidneys, lungs, and spleen at low concentrations (about 4.5% in the kidneys, 1.9% in the lungs, and 0.7% the spleen) at all observed timepoints. Prophylactic studies in a murine model demonstrated a significant bacterial load reduction in the kidneys of the groups treated with either with IgG (greater than 3 logs) or F(ab’)2 (98%) when compared to that of the control groups (untreated). Mice were challenged with a lethal dose, and the survival rate was higher in the treated mice. Treatment with the MAb resulted in a bacterial load reduction in the kidneys similar to that of mice treated with vancomycin, and a MAb/vancomycin combination therapy was also effective. These results demonstrate that an anti-PBP2a MAb may be a promising therapeutic for treating MRSA infections.Keywords
This publication has 18 references indexed in Scilit:
- Complete Genome Sequence of a Variant of the Methicillin-Resistant Staphylococcus aureus ST239 Lineage, Strain BMB9393, Displaying Superior Ability To Accumulate ica -Independent BiofilmMicrobiology Resource Announcements, 2013
- Antibody biodistribution coefficientsmAbs, 2013
- Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in miceJournal of Experimental Medicine, 2010
- Anti-Alpha-Hemolysin Monoclonal Antibodies Mediate Protection againstStaphylococcus aureusPneumoniaInfection and Immunity, 2009
- Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight NeonatesAntimicrobial Agents and Chemotherapy, 2009
- The Third Age of Antimicrobial TherapyClinical Infectious Diseases, 2006
- Characterization of a Protective Monoclonal AntibodyRecognizing Staphylococcus aureus MSCRAMM ProteinClumping FactorAInfection and Immunity, 2003
- The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)Proceedings of the National Academy of Sciences, 2002
- Molecular Analysis of the Accessory Gene Regulator(agr)Locus and Balance of Virulence Factor Expression in Epidemic Methicillin‐ResistantStaphylococcus aureusThe Journal of Infectious Diseases, 2000
- Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1994